Intermediate hepatocellular carcinoma: the role of transarterial therapy

Abstract

According to Barcelona Clinic Liver Cancer, the recommended first-line treatment for patients with intermediate stage of hepatocellular carcinoma (HCC) is transarterial chemoembolization. Patients with intermediate stage of HCC represent 20% with a 2-year survival of approximately 50%. Nowadays, transarterial therapies have proved precious in the treatment of hepatic malignancies. During the last years, there were important developments in practiced transarterial therapies and their efficacy is still controversial. The purpose of this review is to discuss in further details these transarterial therapies that have been used to treat cases of HCC.

Keywords:

• chemoembolization
• DEB TACE
• embolization
• hepatocellular carcinoma
• interventional treatment
• radioembolization
• transarterial chemo-occlusion
• transarterial therapy

Financial & competing interests disclosure

This manuscript was supported by Memorial Sloan Kettering Cancer Center under the institutional NIH grant: P30 CA008748. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Additional information

Funding

This manuscript was supported by Memorial Sloan Kettering Cancer Center under the institutional NIH grant: P30 CA008748. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.